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and therapeutic outcomes of a 7-year-old boy with unilateral CNV secondary to morning glory syndrome associated with acute
visual acuity loss. The patient was successfully treated with a single intravitreal ranibizumab injection. One month after the injection
the visual acuity increased and optic coherence tomography (OCT) showed a decrease in the intraretinal fluid around the CNV. The
patient was then called for monthly follow-up visits. No further treatment was needed for the next 12 months after the first treat-
ment. There was no complication related to the injection.
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Morning glory syndrome (MGS) is an uncommon and uni-
lateral congenital anomaly which was coined by Kindler in
1970.1 The appearance of the anomaly was so similar to the
tropical morning glory flower; therefore, this name was
chosen.1 It is a funnel-shaped excavation of the posterior
pole involving the optic disk. The excavation is filled with a
white tuft of glial tissue and surrounded by a pigment ring.2
The number of retinal vessels is increased, and they appear to
arise from the periphery of the disk, and tend to run to the
peripheral retina.2 Choroidal neovascularization (CNV)
secondary to congenital optic nerve abnormalities is a rare
cause of visual loss in children.3–5 In this case report we aimedto present the clinical and therapeutic outcomes of a 7-year-
old boy with unilateral CNV secondary to MGS.
Case report
A 7-year-old boy was admitted with the complaint of
decreased visual acuity since 5 days in the right eye. Systemic
evaluation was not notable; therefore, cranial magnetic
resonance imaging (MRI) was not obtained. He had a history
of amblyopia in his right eye. His family history was not
significant. On ocular examination, best corrected visual
acuity (BCVA) was 20/100 in the right eye and 20/20 in the
left eye. Slit lamp examination of the anterior segment did




Figure 1. (a) Left photograph shows the infrared imaging of the morning glory disk in the right eye and right photograph shows the optical coherence
tomography scan demonstrating a peripapillary choroidal neovascularization associated with intraretinal fluid (white star). (b) Left photograph shows the
infrared imaging of the morning glory disk in the right eye and right photograph shows the optical coherence tomography scan demonstrating the
decrease in the intraretinal fluid after the ranibizumab injection.
Intravitreal ranibizumab in the treatment of choroidal neovascularization 141normal limits in both eyes. Fundus examination revealed a
morning glory disk and a yellowish subretinal lesion at the
temporal margin of the optic disk in the right eye (Fig. 1a).
The fundus examination was not notable in the left eye. Opti-
cal coherence tomography (OCT) revealed a peripapillary
choroidal neovascularization (CNV) associated with intrareti-
nal fluid at the temporal margin of the optic disk in the right
eye (Fig. 1). Fluorescein angiography (FA) showed the stain-
ing of the peripapillary CNV and a mild leakage (Fig. 2).
Based on ocular findings and the history, the patient was
diagnosed as peripapillary CNV secondary to morning glory
syndrome. Informed consent for intravitreal ranibizumab
injection was obtained from the parents, and 0.5 mg/0.05 ml
intravitreal ranibizumab injection was then performed under
general anesthesia. There was no complication related to
the injection. After 4 weeks of treatment, BCVA improved
to 20/50, and intraretinal fluid decreased significantly
(Fig. 1b). The patient was then called for monthly follow-up
visits, and the peripapillary CNV did not show any kind of
activity (subretinal fluid, intraretinal fluid, visual loss, hemor-
rhage) for the next 12 months.Discussion
The embryogenesis of MGS is not well understood yet.6
Previous studies have suggested that MGS was a primary
mesenchymal abnormality7,8 and it was proposed to be the
result of a faulty closure of the posterior scleral wall and
the poor development of the lamina cribrosa.8 MGS was
often associated with persistent hyperplastic primary vitreous
(PHPV).9 Fei et al. reported that the coexistence of PHPV in asignificant percentage of patients with MGS, might suggest a
potential common genetic link between the two disorders.9
They added that compared with MGS or PHPV alone, the
combination of the two conditions might manifest with
higher incidence of more severe complications.9 The same
study reported that PAX6 mutations that have also been
identified in patients with optic nerve malformations, includ-
ing coloboma, MGS, optic nerve hypoplasia/aplasia and
PHPV might play an important role on the pathogenesis.9,10
However some other reports revealed that not all patients
with MGS have the PAX6 mutation.10 Another common co-
existing disorder with MGS is basal encephalocele.11 Sasani
et al. reported that the presence of ophthalmologic findings
such as strabismus in association with anomalies of optic
nerve should always bring in mind the possible presence of
an unrecognized skull base midline defect and encephalo-
cele.11 The systemic associations of MGS are usually uncom-
mon, and if present cranial anomalies are associated with
mid-facial anomalies such as hypertelorism and flat nasal
bridge. Mid-facial anomalies, basal encephalocele, and mid-
line brain malformations are coined as frontonasal dyspla-
sia.1,6,10 As our patient did not show any abnormality in
clinical examination we did not obtain cranial MRI from him.
Strabismus may be the first symptom and serous retinal
detachment may develop in up to 30% of patients with
MGS.12 However CNV secondary to MGS is very rare.3–5
There is no established treatment regimen yet. Anti-VEGF
therapy is currently indicated for the treatment of CNV, mac-
ular edema associated with vascular occlusion or diabetes
mellitus and retinopathy of prematurity. Only a few cases of
CNV secondary to MGS is reported in the literature.3–5 Two
of the reported cases who were in adulthood were treated
Figure 2. Right eye, fluorescein angiography reveals the staining of the peripapillary CNV and mild leakage in different phases before the treatment
(white arrows).
142 A. Özkaya et al.with intravitreal anti-VEGF agents.4,5 The first case was
reported to be a 51-year-old male and received 2 intravitreal
bevacizumab injections during the 6 month follow-up period.
The visual acuity of the patient was reported to be increased
from 0.1 to 0.6 in decimals.4 The second case was a 63-year-
old woman who received three consecutive monthly ranibizu-
mab injections and did not require any additional injections
for the next 24 months. The visual acuity of the patient was
reported to increase from 0.7 LogMAR to 0.1 LogMAR and
remained stable for the next 24 months.5 In the current
report we used a single intravitreal injection of ranibizumab
for the treatment of peripapillary CNV secondary to MGS in
a 7-year-old boy and no recurrence was observed during
the 12 month follow-up period.Conclusion
To our knowledge this is the first case of CNV secondary
to morning glory syndrome in a child treated with ranibizu-
mab. Peripapillary CNV secondary to optic nerve abnormali-
ties may be successfully treated with intravitreal ranibizumab
injections. This report adds to the evidence base accumulat-
ing for the use of ranibizumab in a case of CNV secondary to
MGS. Flexible treatment regimens should be advised in pedi-
atric patients rather than monthly injections in these settings.Conflict of interest
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